Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The employee equity awards vest over three years, subject to continued service.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Intellia Therapeutics (NTLA) awarded inducement grants covering 12,900 common shares to new employees on November 1, 2026, as an employment incentive.
The grants to three employees consist of restricted stock units (RSUs), with one-third vesting annually over three years. Vesting requires continued service through each applicable vesting date. The compensation committee approved the awards under Nasdaq Listing Rule 5635(c)(4). They were granted outside stockholder-approved equity incentive plans under the amended 2024 Inducement Plan.
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.RSUs covering 12,900 common shares represent potential dilution as employee awards vest.
Key Figures
- Aggregate RSUs
- 12,900 shares
- Inducement grants to three new employees
- Vesting schedule
- One-third annually over three years
- Time-based restricted stock units
Key Terms
restricted stock units financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on November 1, 2026, it awarded inducement grants to three new employees as a material inducement to employment.
The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate of 12,900 shares of Intellia’s common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.
All of the above-described awards were granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, as amended, which was initially adopted by the board of directors in June 2024. These awards were approved by Intellia’s compensation committee as a material inducement to entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).
About Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.
Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
jason.fredette@intelliatx.com
Media Contact:
Mike Tattory
Vice President
LifeSci Communications
mtattory@lifescicomms.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.